Friday, March 29, 2024 9:31:12 AM
Recent NUVB News
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 10/10/2024 08:33:51 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 10/09/2024 08:09:53 PM
- Form 3 - Initial statement of beneficial ownership of securities • Edgar (US Regulatory) • 10/09/2024 08:09:11 PM
- Nuvation Bio Appoints Industry Veteran Philippe Sauvage as Chief Financial Officer • Business Wire • 10/07/2024 08:05:00 PM
- Positive Pooled Data from Nuvation Bio’s TRUST-I and TRUST-II Studies Highlight Taletrectinib’s Best-in-Class Potential for Patients with Advanced ROS1-positive NSCLC, Supporting Planned New Drug Application Submission in the Fourth Quarter of 2024 • Business Wire • 09/14/2024 07:05:00 AM
- Nuvation Bio to Present at the Cantor Global Healthcare Conference • Business Wire • 09/09/2024 12:00:00 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 09/05/2024 08:46:57 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 09/05/2024 08:35:57 PM
- Form EFFECT - Notice of Effectiveness • Edgar (US Regulatory) • 08/16/2024 04:15:17 AM
- Form 424B3 - Prospectus [Rule 424(b)(3)] • Edgar (US Regulatory) • 08/15/2024 08:46:11 PM
- Form DEFR14A - Revised definitive proxy soliciting materials • Edgar (US Regulatory) • 08/13/2024 08:02:49 PM
- Form S-3 - Registration statement under Securities Act of 1933 • Edgar (US Regulatory) • 08/05/2024 08:58:34 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 08/05/2024 12:44:08 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 08/05/2024 12:37:33 PM
- Nuvation Bio Reports Second Quarter 2024 Financial Results and Provides Business Update • Business Wire • 08/05/2024 12:00:00 PM
- Form DEF 14A - Other definitive proxy statements • Edgar (US Regulatory) • 07/30/2024 08:01:55 PM
- Nuvation Bio Announces Updates and Upcoming Presentations for its ROS1 Inhibitor, Taletrectinib • Business Wire • 07/23/2024 08:05:00 PM
- Form PRER14A - Preliminary Proxy Soliciting materials • Edgar (US Regulatory) • 07/16/2024 01:03:25 PM
- Nuvation Bio Announces Data from Pivotal Phase 2 TRUST-I Study of its Investigational ROS1 Inhibitor, Taletrectinib, are Published in the Journal of Clinical Oncology and Reported at 2024 ASCO Annual Meeting • Business Wire • 06/01/2024 12:10:00 PM
- Nuvation Bio to Present at the Jefferies Global Healthcare Conference • Business Wire • 05/29/2024 08:05:00 PM
- Form PRER14A - Preliminary Proxy Soliciting materials • Edgar (US Regulatory) • 05/24/2024 09:22:30 PM
- Form PRE 14A - Other preliminary proxy statements • Edgar (US Regulatory) • 05/24/2024 08:40:56 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 05/14/2024 08:28:41 PM
CBD Life Sciences Inc. (CBDL) Launches High-Demand Mushroom Gummy Line for Targeted Wellness Needs, Tapping into a Booming $20 Billion Market • CBDL • Oct 31, 2024 8:00 AM
Nerds On Site Announces Q1 Growth and New Initiatives for the Remainder of 2024 • NOSUF • Oct 31, 2024 7:01 AM
Innovation Beverage Group Receives Largest Shipment of its Top-Selling Bitters to Date in the U.S.-Ready to Meet Growing Demand from Expanding Distribution Network • IBG • Oct 30, 2024 12:22 PM
Element79 Gold Corp to Update Investors on the Emerging Growth Conference on October 31, 2024 • ELMGF • Oct 30, 2024 9:08 AM
CBD Life Sciences Inc. (CBDL) Announces Grand View Research Report Findings on High - Growth CBD Equine Market, Aiming to Drive Unprecedented Shareholder Value • CBDL • Oct 29, 2024 10:19 AM
Integrated Ventures Announces Partnership And Lease Agreement with Driptide Wellness - Leading Health and Wellness Provider. • INTV • Oct 29, 2024 8:45 AM